Clinical trials: Obesity & Overweight Sleep
Obesity Hypoventilation Syndrome
Toffee Full Face and Toffee Nasal Mask Evaluation in Obesity Hypoventilation Syndrome (NZ)
This investigation is to evaluate the performance, comfort and ease of use of the Toffee full face and toffee nasal mask masks amongst Obesity Hypoventilation Syndrome (OHS) patients in an overnight study.
- Trial name
- NCT02486380
- Testing
- Toffee full face mask/toffee nasal mask
- Where
- New Zealand
- Volunteers
- 4 people
- Sponsor
- Fisher and Paykel Healthcare
Obesity Hypoventilation Syndrome
AVAPS-AE Efficacy Study
The purpose of this study is to evaluate the feasibility of using of the Average Volume Assured Pressure Support (AVAPS-AE) mode versus Continuous Positive Airway Pressure (CPAP) and bilevel pressure support ventilation (PSV)…
- Trial name
- NCT01368614
- Testing
- AVAPS-AE Mode of Therapy, Respironics OnmiLab BiPAP S mode, Respironics OmniLab Advanced CPAP mode
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- Philips Respironics
Obesity, Obstructive Sleep Apnea
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy
This Phase 3 clinical trial is designed to evaluate the efficacy and safety of maridebart cafraglutide compared to placebo over a 52-week period in adults with obstructive sleep apnea (OSA) who are receiving positive airway…
- Trial name
- MARITIME-OSA-1 (NCT07225686)
- Testing
- Maridebart cafraglutide
- Where
- 61 sites in United States, Australia and 9 more
- Volunteers
- 250 people
- Sponsor
- Amgen
Obstructive Sleep Apnea, Obesity
UBT251 Injection Phase Ⅲ Study (OSA-PAP)
UBT251 will be compared with placebo (an inactive substance identical in appearance) to evaluate its therapeutic effect in participants with moderate-to-severe obstructive sleep apnea maintained on positive airway pressure…
- Trial name
- UNISHAPE-OSA-2 (NCT07806851)
- Testing
- UBT251
- Volunteers
- 150 people
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
OSA - Obstructive Sleep Apnea, Obesity
A Study of XW003 in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure Therapy
The aim of the study is to assess the efficacy and safety of XW003 injections in obese participants with OSA receiving PAP
- Trial name
- NCT07434050
- Testing
- XW003 injection
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
Obstructive Sleep Apnea (OSA) and Obesity
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HDM1005 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Not Receiving Positive Airway Pressure (PAP) Therapy
This is a 56-week randomized, double blinded, parallel-controlled study evaluating the efficacy and safety of the HDM1005 in patients with obstructive sleep apnea (OSA) and obesity not receiving positive airway pressure (PAP)…
- Trial name
- NCT07787260
- Testing
- HDM1005
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Obesity Hypoventilation Syndrome
Target Volume Mode Controlled Ventilator in Obesity Hypoventilation Syndrome
The purpose of this study is to investigate the evolution of daytime partial pressure of carbon dioxide in the blood (PaCO2) after 6 weeks of noninvasive ventilation-pressure support ventilation (NIV-PSV) with target volume…
- Trial name
- OVO (NCT01104610)
- Testing
- Breas Vivo 40
- Where
- 2 sites in France
- Sponsor
- Breas Medical S.A.R.L.
OSA, Overweight or Obesity
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Study GZRA is a master protocol that will support 2 independent studies, GZ01 and GZ02. Participants will be assigned to the appropriate study prior to randomization.
- Trial name
- ATTAIN-OSA (NCT06649045)
- Testing
- Orforglipron
- Where
- 66 sites in United States, Argentina and 7 more
- Volunteers
- 712 people
- Sponsor
- Eli Lilly and Company
COPD (Chronic Obstructive Pulmonary Disease), Obesity Hypoventilation Syndrome (OHS)
The Effect of Mask Design on Ventilation Parameters in COPD and OHS Patients on Long-term Home Non-invasive Ventilation. An Experimental Study.
Chronic obstructive pulmonary disease (COPD) and obesity hypoventilation syndrome (OHS) are respiratory conditions that disrupt normal breathing.
- Trial name
- NCT06972589
- Testing
- Investigational Mask, Conventional mask
- Where
- New Zealand
- Volunteers
- 20 people
- Sponsor
- Fisher and Paykel Healthcare
Quality of Life, Obesity
Effect of Consumption of Pep19 on Quality of Life
Pep19 is a naturally occurring peptide (protein) that triggers loss of body fat. It has been certified Generally Recognized as Safe (GRAS) at up to 3.8 grams per day and may be included in various foods.
- Conditions
- Quality of Life, Obesity, Sleep Quality
- Trial name
- NCT06359327
- Testing
- Pep19 2 mg, Pep19 5 mg
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Proteimax Biotechnology Israel LTD